📊 UTMD Key Takeaways
Is Utah Medical Products Inc. (UTMD) a Good Investment?
UTMD demonstrates fortress-like financial health with a 97% equity-financed balance sheet, exceptional 29.9% net margins, and $87.4M in cash, but faces material business headwinds with revenue declining 5.8% YoY and net income falling 18.7%. The critically low ROE of 2.2% and ROA of 2.1% indicate significant capital inefficiency despite strong profitability, suggesting excess idle capital without effective deployment or growth catalysts.
Utah Medical Products Inc. Key Strengths (UTMD)
- Fortress balance sheet: $120.4M equity, $4.0M liabilities, debt-free with $210K long-term debt
- Exceptional profitability margins: 60.6% gross, 29.4% operating, 29.9% net margin
- Outstanding cash generation: $3.0M FCF with 34.2% FCF margin; minimal $130K CapEx
- Extreme liquidity: 28.64x current ratio, 39.5x interest coverage ratio
UTMD Stock Risks: Utah Medical Products Inc. Investment Risks
- Revenue decline of 5.8% YoY indicates top-line business deterioration in medical device sector
- Net income dropped 18.7% YoY, faster than revenue decline, suggesting margin compression or operating deleveraging
- Critically low returns: ROE 2.2% and ROA 2.1% despite high margins indicates severe capital inefficiency with $87.4M underdeployed
- EPS declined 12.1% YoY; no insider buying activity to suggest management confidence
Key Metrics to Watch
- Revenue growth trajectory and stabilization; address the 5.8% YoY decline
- Return on Equity trend; 2.2% is untenable for a profitable company and suggests capital redeployment or M&A activity
- Operating margin sustainability; monitor for further compression below 29.4%
- Cash deployment strategy; clarify if $87.4M is strategic reserve or indicates business opportunity constraint
Utah Medical Products Inc. (UTMD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 34.2% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 28.64x current ratio provides a solid financial cushion.
UTMD Profit Margin, ROE & Profitability Analysis
UTMD vs Healthcare Sector: How Utah Medical Products Inc. Compares
How Utah Medical Products Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Utah Medical Products Inc. Stock Overvalued? UTMD Valuation Analysis 2026
Based on fundamental analysis, Utah Medical Products Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Utah Medical Products Inc. Balance Sheet: UTMD Debt, Cash & Liquidity
UTMD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Utah Medical Products Inc.'s revenue has shown modest growth of 2% over the 5-year period. The most recent EPS of $1.16 reflects profitable operations.
UTMD Revenue Growth, EPS Growth & YoY Performance
UTMD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $8.7M | $2.6M | $0.82 |
| Q3 2025 | $9.8M | $2.6M | $0.82 |
| Q2 2025 | $10.0M | $3.0M | $0.94 |
| Q1 2025 | $9.7M | $3.0M | $0.92 |
| Q3 2024 | $10.0M | $3.6M | $1.02 |
| Q2 2024 | $10.4M | $3.5M | $0.98 |
| Q1 2024 | $11.3M | $4.0M | $1.09 |
| Q3 2023 | $12.5M | $3.9M | $1.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Utah Medical Products Inc. Dividends, Buybacks & Capital Allocation
UTMD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Utah Medical Products Inc. (CIK: 0000706698)
📋 Recent SEC Filings
❓ Frequently Asked Questions about UTMD
What is the AI rating for UTMD?
Utah Medical Products Inc. (UTMD) has an AI grade of B with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are UTMD's key strengths?
Claude: Fortress balance sheet: $120.4M equity, $4.0M liabilities, debt-free with $210K long-term debt. Exceptional profitability margins: 60.6% gross, 29.4% operating, 29.9% net margin.
What are the risks of investing in UTMD?
Claude: Revenue decline of 5.8% YoY indicates top-line business deterioration in medical device sector. Net income dropped 18.7% YoY, faster than revenue decline, suggesting margin compression or operating deleveraging.
What is UTMD's revenue and growth?
Utah Medical Products Inc. reported revenue of $8.7M.
Does UTMD pay dividends?
Utah Medical Products Inc. pays dividends, with $1.0M distributed to shareholders in the trailing twelve months.
Where can I find UTMD SEC filings?
Official SEC filings for Utah Medical Products Inc. (CIK: 0000706698) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is UTMD's EPS?
Utah Medical Products Inc. has a diluted EPS of $0.82.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is UTMD's fundamental grade?
Based on our AI fundamental analysis in June 2026, Utah Medical Products Inc. has a B grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is UTMD stock overvalued or undervalued?
Valuation metrics for UTMD: ROE of 2.2% (sector avg: 15%), net margin of 29.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is UTMD's AI grade for 2026?
Our dual AI analysis gives Utah Medical Products Inc. a combined B grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is UTMD's free cash flow?
Utah Medical Products Inc.'s operating cash flow is $3.1M, with capital expenditures of $130.0K. FCF margin is 34.2%.
How does UTMD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 29.9% (avg: 12%), ROE 2.2% (avg: 15%), current ratio 28.64 (avg: 2).